Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.52 |
| ▸ | P2RY2 | P41231 | 15/20 | 0.49 |
| ▸ | P2RY4 | P51582 | 9/20 | 0.49 |
| ▸ | POLA1 | P09884 | 1/20 | 0.49 |
| ▸ | POLG | P54098 | 1/20 | 0.47 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1129230 | 0.98 | DUT (0.54) | DUTP2RY2P2RY4POLA1POLG | |
| SCHEMBL475343 | 0.90 | DUT (0.52) | DUTP2RY2P2RY4P2RY6 | |
| SCHEMBL7745800 | 0.88 | DUT (0.55) | DUTP2RY2P2RY4POLA1P2RY6 | |
| SCHEMBL150273 | 0.88 | DUT (0.52) | DUTP2RY2P2RY4POLA1P2RY6 | |
| SCHEMBL8441083 | 0.88 | DUT (0.52) | DUTP2RY2P2RY4POLA1P2RY6 | |
| SCHEMBL16670190 | 0.87 | DUT (0.51) | DUTP2RY2P2RY4POLA1P2RY6 | |
| SCHEMBL8439797 | 0.87 | DUT (0.51) | DUTP2RY2P2RY4POLA1P2RY6 | |
| SCHEMBL21647246 | 0.86 | DUT (0.48) | DUTP2RY2P2RY4P2RY6 | |
| SCHEMBL14855438 | 0.86 | DUT (0.50) | DUTP2RY2P2RY4POLA1P2RY6 | |
| SCHEMBL8436034 | 0.86 | DUT (0.52) | DUTP2RY2P2RY4POLA1P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025151105-A1 | 5-FLUOROURACIL AND GENTISIC ACID LOADED NANOPARTICLE COATED WITH BIOTIN | YILDIZ TEKNİK ÜNİVERSİTESİ DÖNER SERMAYE İŞLETME MÜD (TR) | 2025-07-17 | — | — | WO | disclosed |
| US-20240415837-A1 | PHARMACOLOGIC MODULATION OF 5-FLUOROURACIL BY FOLINIC ACID AND VITAMIN B6 FOR THE TREATMENT OF PATIENTS WITH CARCINOMA | MACHOVER DAVID (FR) | 2024-12-19 | — | — | US | disclosed |
| EP-4419107-A1 | PHARMACOLOGIC MODULATION OF 5-FLUOROURACIL BY FOLINIC ACID AND VITAMIN B6 FOR THE TREATMENT OF PATIENTS WITH CARCINOMA | Machover, David (FR) | 2024-08-28 | — | — | EP | disclosed |
| WO-2023066865-A1 | PHARMACOLOGIC MODULATION OF 5-FLUOROURACIL BY FOLINIC ACID AND VITAMIN B6 FOR THE TREATMENT OF PATIENTS WITH CARCINOMA | MACHOVER DAVID (FR) | 2023-04-27 | — | — | WO | disclosed |
| US-11612653-B2 | Anti-tumor agent containing immunomodulator, and antitumor effect potentiator | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-03-28 | — | — | US | disclosed |
| CN-115137719-A | Application of small molecular compound in reversing drug resistance of colorectal cancer chemotherapy | 浙江省肿瘤医院 | 2022-10-04 | — | — | CN | disclosed |
| EP-3693019-A1 | ANTI-TUMOR AGENT CONTAINING IMMUNOMODULATOR | Taiho Pharmaceutical Co., Ltd. (JP) | 2020-08-12 | — | — | EP | disclosed |
| US-10722530-B2 | Methods of diagnosing and treating cancer | CASE WESTERN RESERVE UNIVERSITY (US) | 2020-07-28 | — | — | US | disclosed |
| US-20190046639-A1 | ANTI-TUMOR AGENT CONTAINING IMMUNOMODULATOR, AND ANTITUMOR EFFECT POTENTIATOR | TAIHO PHARMACEUTICAL CO., LTD (JP) | 2019-02-14 | — | — | US | disclosed |
| EP-3400963-A1 | ANTI-TUMOR AGENT CONTAINING IMMUNOMODULATOR, AND ANTI-TUMOR EFFECT ENHANCER | Taiho Pharmaceutical Co., Ltd. (JP) | 2018-11-14 | — | — | EP | disclosed |
| US-20100166848-A1 | LIPOSOMAL FORMULATIONS FOR TREATING CANCER | ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE (FR) | 2010-07-01 | — | — | US | disclosed |
| EP-2187868-A1 | LIPOSOMAL FORMULATIONS FOR TREATING CANCER | Université de la Méditerranée (FR) | 2010-05-26 | — | — | EP | disclosed |
| WO-2010025308-A2 | INHIBITORS OF DUTPASE | UNIVERSTIY OF SOUTHERN CALIFORNIA (US) | 2010-03-04 | — | — | WO | disclosed |
| WO-2009121183-A1 | DISPERSINBTM, 5-FLUOROURACIL, DEOXYRIBONUCLEASE I AND PROTEINASE K-BASED ANTIBIOFILM COMPOSITIONS AND USES THEREOF | KANE BIOTECH INC. (CA) | 2009-10-08 | — | — | WO | disclosed |
| WO-2009034148-A1 | LIPOSOMAL FORMULATIONS FOR TREATING CANCER | UNIVERSITE DE LA MEDITERRANEE (FR) | 2009-03-19 | — | — | WO | disclosed |
| US-20090042187-A1 | COMPOSITIONS AND METHODS FOR PREDICTING OUTCOME OF TREATMENT | DAKO DENMARK APS (DK) | 2009-02-12 | — | — | US | disclosed |
| EP-1885878-A2 | COMPOSITIONS AND METHODS FOR PREDICTING OUTCOME OF TREATMENT | Dako Denmark A/S (DK) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006128463-A2 | COMPOSITIONS AND METHODS FOR PREDICTING OUTCOME OF TREATMENT | DAKO DENMARK A/S (DK) | 2006-12-07 | — | — | WO | disclosed |
| US-20020183277-A1 | Combination of vitamin D analogue and pyrimidine nucleoside analogue | BINDERUP LISE (DK) | 2002-12-05 | — | — | US | disclosed |
| WO-2002092062-A2 | COMBINATION OF VITAMIN D ANALOGUE AND PYRIMIDINE NUCLEOSIDE ANALOGUE | LEO PHARMA A/S (DK) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10722530-B2 | Methods of diagnosing and treating cancer | UNG, TP53, OGG1 | DUT 15/4885P2RY2 4554/4885P2RY4 4439/4885 |
| US-20190046639-A1 | ANTI-TUMOR AGENT CONTAINING IMMUNOMODULATOR, AND ANTITUMOR EFFECT POTENTIATOR | NFATC1, DCLRE1B, DNASE1L3 | DUT 67/4885P2RY2 3143/4885P2RY4 2867/4885 |
| US-20090042187-A1 | COMPOSITIONS AND METHODS FOR PREDICTING OUTCOME OF TREATMENT | TP53, CD74, TSG101 | DUT 771/4885P2RY2 3861/4885P2RY4 4061/4885 |
| US-20020183277-A1 | Combination of vitamin D analogue and pyrimidine nucleoside analogue | DCTD, VDR, DPYD | DUT 15/4885P2RY2 640/4885P2RY4 356/4885 |
| US-11612653-B2 | Anti-tumor agent containing immunomodulator, and antitumor effect potentiator | NFATC1, DCLRE1B, DNASE1L3 | DUT 67/4885P2RY2 3143/4885P2RY4 2867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.